Non-hallucinogenic psychedelic fungi
AssigneeLuminous Mind Inc.
InventorsLouis Herlands, David Thaler, John Myles Axton
Life of this patent
Estimating the term…
Loading patent…
AssigneeLuminous Mind Inc.
InventorsLouis Herlands, David Thaler, John Myles Axton
Estimating the term…
The present invention provides genetically modified fungi, such as non-hallucinogenic psychedelic fungi, in which a biochemical pathway to produce a bioactive alkaloid is disrupted. In some aspects, the psilocybin biosynthesis pathway is disrupted, resulting in non-hallucinogenic psychedelic fungi which do not produce or contain psilocybin, or which produce or contain a substantially reduced amount of psilocybin relative to wild-type fungi. Also provided are methods of making genetically modified fungi, for example by disrupting or rebalancing a biochemical pathway therein, such as the psilocybin biosynthesis pathway, such as by using gene editing techniques, including gene inactivation by small interfering RNAs (siRNAs), microRNAs (miRNAs), and CRISPR/Cas9. Also provided are compositions of genetically modified fungi, such as compositions of non-hallucinogenic psychedelic fungi, and methods of their use, including as functional foods, nootropics, legal microdoses, nutraceuticals, and therapeutics.
A non-hallucinogenic psychedelic Psilocybe spp. fungus having reduced production of a bioactive alkaloid, wherein the fungus has disrupted activity of one or more of a PsiD, PsiH, PsiK, or PsiM enzyme, wherein the disrupted activity is a result of disrupted expression of one or more of a PsiD, PsiH, PsiK, or PsiM gene using an siRNA.
Dependencies are inferred from the claim text.